Asthma is a global health burden that affects all age
groups1
. It is characterized by the presence of chronic
airway inflammation. Hence, inhaled corticosteroids
are the mainstay of asthma management2.
International guidelines recommend medium or high
dose inhaled corticosteroid (ICS) and long acting
inhaled β2
-agonists (LABAs) combinations (dual
therapy), delivered from the same inhaler, as the
preferred controller options for patients with moderate
to severe asthma3.
 

Download PDF